ClinicalTrials.gg
RecruitingNCT04652310Updated May 29, 2024

Long vs Extended-short Nail When Treating Proximal Femur Fractures

An interventional study of TFNA extended-short nail (235 mm) and TFNA long nail (260-480mm) in Hip Fractures, sponsored by Vestre Viken Hospital Trust. Recruiting at 2 sites in Norway. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by Vestre Viken Hospital Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Hip Fractures with a site in Norway — 4 open to participants now, 6 under way, none of them phase 3. Hip Fractures · Norway.

Planned enrollment
4th of 25
800 · median 200
Started
2020
with 1 other
No phase
20 of 30
4 open now
Registered
24th of 30
by date
Lead sponsor
2 of 30
Vestre Viken Hospital Trust

Among the 30 studies in Hip Fractures with a site in Norway, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2020, is one of 20 with no phase, and was the 24th registered.

Hip Fractures

843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.

Browse Hip Fractures studies →

Open to participants now

4 of the 30 studies in Hip Fractures with a site in Norway are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hip Fractures with a site in Norway, or all of them as a file.
02

Study summary

Fractures of the upper part of the femur may be treated with intramedullary nails. There are different designs to choose from. The intention of this RCT is to compare two nails with some of the same properties, but with different lengths. Usually, it is the surgeon who decides which nail to be used. The literature indicates that there is a lack of good evidence in the decision-making, and that the choice often depends on personal preferences and experience of the surgeon. Therefore, the investigators want to compare whether one of the nails has a better outcome than the other, and in that way be able to give some clearer guidelines for treatment. Patients will be randomized into two groups, one receiving a long nail and one receiving an extended-short nail and compare surgical and functional outcomes. Information from the operation and subsequent check-ups will be analysed. The hypothesis is that the extended-short nail can reduce operating time, bleeding, fluoroscopy time and give equal or better functional outcome, without increasing reoperation rates or mortality.

Read the detailed description

Background Intramedullary nails have in recent years become the preferred technique compared to DHS when treating proximal femur fractures. A Norwegian RCT has showed the same frequency of postoperative pain, functional outcome and rate of reoperations comparing the two techniques. Nails are usually provided in a long and short model. Deciding which nail length to use is highly discussed, and often a long nail is preferred, because it gives a theoretically more stable and secure fixation of the femur. There are, however many advantages of using a short nail. It is less time consuming as there is no need for reaming, securing the long nail distally requires more fluoroscopy time, and distal locking of the long nail has also been shown to increase the risk of perioperative fractures. Perioperative bleeding and postoperative blood transfusions are reduced when using a short nail, and a long nail may also give more pain distally around the thigh and around the knee owing to cortical impingement. Finally, the long nail is more expensive compared to short models. There is a perception in the orthopedic society that there's a higher risk of periprosthetic fractures with short nails, but the latest generations of nails have improved this problem. Most studies report no difference in periprostetic fractures between long and short nails. Recently, new extended-short versions of medullary nails are being produced. The extended-short nail combines the mechanical properties seen in a long nail and the surgical simplicity of a short nail. This new nail type may replace the use of several long nails being placed just to be on the safe side, and thus reduce operating time, bleeding and postoperative pain associated with a long nail. Biomechanical studies have showed that the mechanical properties of long and extended-short nails are predominantly comparable, but to our knowledge no clinical studies comparing the extended-short and long nails have been performed to date. The advantages of an extended-short nail are potentially great, which makes it important to clarify which opportunities there are to benefit from this type of nail for certain types of fractures, both in the interest of the patient as well as the economic healthcare perspective.

Purpose In a well-defined population of patients with proximal femur fractures within a certain anatomical area the aim is to compare the extended-short nail with the long nail, to evaluate differences in functional and surgical outcome.

03

Conditions studied

  • Hip Fractures

Browse trials for

Keywords

  • intramedullary nailing
  • TFNA
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Intertrochanteric, pertrochanteric or subtrochanteric fractures
  • Distal fracture limit within 4 cm below the trochanter minor
  • Intramedullary nailing with TFNA-nail is indicated
  • Patient is fit for surgery.

Exclusion criteria

Exclusion Criteria:

  • AO 31-A3 fractures (revers oblique fractures)
  • Cognitively impaired patients who themselves cannot understand the study information and give , and do not have a next of kin or legal guardian who can give consent on their behalf.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
800 participants (estimated)

Study arms

  • Active comparator
    Extended-Short Nail

    Implantation of TFNA extended-short nail (235 mm)

    Device: TFNA extended-short nail (235 mm)

  • Active comparator
    Long nail

    Implantation of TFNA long nail (260-480 mm)

    Device: TFNA long nail (260-480mm)

Interventions

  • DeviceTFNA extended-short nail (235 mm)

    The extended short version of the TFN-advanced proximal femoral nailing system (TFNA)

    Also known as: TFN-advanced proximal femoral nailing system (TFNA) 235 mm

  • DeviceTFNA long nail (260-480mm)

    The long version of the TFN-advanced proximal femoral nailing system (TFNA)

    Also known as: TFN-advanced proximal femoral nailing system (TFNA) 260-480mm

06

What researchers measure

Primary outcomes

  1. Difference in Short Physical Performance Battery (SPPB)-score

    Short Physical Performance Battery (SPPB)-score, ranges from 0-12, 12 is the best indicating a good physical function.

    Time frame: At 3 months and 1 year

Secondary outcomes

  1. Difference in Operation time

    Operation time in minutes

    Time frame: Surgery date

  2. Difference in Blood loss

    Blood loss during surgery

    Time frame: Surgery date

  3. Difference in Harris Hip score

    Harris Hip score, ranges from 0-100, 100 is the best score, a high score indicates good physical function.

    Time frame: 3 months and 1 year

  4. Difference in EQ5D-5L (EuroQoL 5L - health-related quality of life)

    EQ5D-5L (EuroQoL 5L - health-related quality of life)measures health status terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. The respondents self-rate their level of severity for each dimension using three-level (EQ-5D-3L) or five-level (EQ-5D-5L) scale

    Time frame: 3 months and 1 year

  5. Difference in Transfusion after surgery

    Need for transfusion of blood products after surgery

    Time frame: 2 weeks after surgery

  6. Difference in Fluoroscopy time

    Fluoroscopy time during surgery

    Time frame: Surgery date

  7. Difference in Postoperative complications

    Any postoperative complications

    Time frame: Minimally 1 year

  8. Difference in Mortality

    Mortality after surgery

    Time frame: Minimally 1 year

  9. Difference in Reoperations

    Reoperations of any kind

    Time frame: Minimally 1 year

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Nov 2024, 47 months after the start.

Of 221 non-industry interventional studies with no phase under Hip Fractures, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 55. This study's planned 47 months is above that.

Counting every sponsor, half of 237 studies reached it within 29 months; a quarter within 10 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2020
First posted
Dec 3, 2020
StartActual
Dec 1, 2020
Primary completionEst.
Nov 2024
CompletionEst.
Dec 2025
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04652310
Lead sponsor
Vestre Viken Hospital Trust
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Dec 1, 2020
Primary completion
Nov 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
May 29, 2024

Study contacts

Heidi B Dyrop, MD, PHD
Contact
heidyr@vestreviken.no
+4799030104
Andreas Stangeby, MD
Contact
antsta@vestreviken.no
+4793457441
Heidi B Dyrop, MD, PHD
principal investigator · Orthopedic Dpt, Kongsberg Hospital, Vestre Viken HF

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion